Hassan Sobia, Syed Serajuddaula, Kehar Shahnaz Imdad
J Pak Med Assoc. 2014 Aug;64(8):941-5.
With increasing innovations aimed at the treatment of chronic liver disease (CLD), the precise staging of liver fibrosis is important to help establish efficacious management of disease activity in each patient. The development of biomarkers capable of non-invasive staging of fibrosis in the liver is challenging as fibrogenesis is a part of the normal wound healing response. There is an array of non-invasive methods, including serum biomarker assays, and imaging techniques such as transient elastography. The degree of implementation of non-invasive diagnostic tests for liver fibrosis differs all over the world, and still remains limited. Liver biopsy so far is the mainstay of diagnosing hepatic fibrosis. Precise staging of liver fibrosis is essential in management of patients. This review provides a systematic overview of various techniques, as well as both approaches based on direct and indirect biomarkers to stage fibrosis, and covers recent studies related to hepatic fibrosis.
随着针对慢性肝病（CLD）治疗的创新不断增加，肝纤维化的精确分期对于帮助确定每位患者疾病活动的有效管理至关重要。由于纤维生成是正常伤口愈合反应的一部分，因此开发能够对肝脏纤维化进行非侵入性分期的生物标志物具有挑战性。有一系列非侵入性方法，包括血清生物标志物检测以及诸如瞬时弹性成像等成像技术。肝纤维化非侵入性诊断测试的实施程度在世界各地各不相同，并且仍然有限。迄今为止，肝活检仍是诊断肝纤维化的主要方法。肝纤维化的精确分期对于患者的管理至关重要。本综述系统概述了各种技术以及基于直接和间接生物标志物对纤维化进行分期的两种方法，并涵盖了与肝纤维化相关的最新研究。
